Bio-Rad Laboratories Inc. is in talks to combine with fellow life-sciences company Qiagen NV in a deal that would be worth more than $10 billion, according to people familiar with the matter.
The talks have been going on for a while, but any agreement isn’t likely for another few weeks or more — and there may not be one.
A deal between Qiagen and Bio-Rad would be the latest tie-up in the medical-diagnostic market, which has grown as the pandemic helped increase demand for testing.
Trending at WSJ.com:
More biotech and health news: